Sun Pharma Launches World’s First Licensed Ready-To-Administer Oncology Product
Sun Pharma’s R&D team in India developed gemcitabine InfuSMART technology which is a ready-to-administer (RTA) bag for oncology treatment.
The announcement of the company to roll out gemcitabine InfuSMART in Europe made it the world’s first pharmaceutical company to develop and launch a licensed oncology RTA product. The company plans to launch the product in six other countries-Netherlands, Spain, UK, Germany, Italy and France in next few months.
InfuSMART is a mechanization in which oncology products are developed in an RTA bag. Till now, oncology products were being compounded at various compounding centers or in hospital pharmacies before the medicine could be administered to the patients.
Sun Pharma’s gemcitabine InfuSMART is a ready-to-administer infusion technology which will be readily available to the patients in need. Therefore, it will remove the time consuming and potentially hazardous compounding practice. This innovative and unique product will have a shelf life of two years.
Gemcitabine is used in the treatment of ovarian, lung, breast and pancreatic cancer. The company hinted that in the coming times it will come up with more InfuSMART oncology products. The InfuSMART technology utilizes the dose banding practice where the patient’s waiting time can be reduced and capacity planning of pharmacy can be enhanced by preparing the long-stable compounded medicine in advance by the collaboration of prescribers and pharmacists.The dose banding can also reduce wastage of drug and medication errors.
Ms Hellen de Kloet, Business Head – Western Europe & ANZ, Sun Pharma said, “Launch of InfuSMART will help us remain a meaningful player in the global oncology therapy market by offering differentiating cancer treatment solutions. We believe there are opportunities for us to expand our portfolio of ready-to-administer products across multiple therapies where time and safety are an important element of treatment.”
Sun Pharma is absolutely expediting its efforts to build an internationally recognized products, business and has classified regions where it feels considerable need gaps exist. The InfuSMART is expected to play an increasing role due to improved security, convenient, and suitable benefits.
World Health Organization (WHO) data have shown that about 14 million new cases of cancer were detected in 2012 while 8.2 million died during 2012 due to cancer. Such figures are signs of unavoidable threats which need to be looked upon seriously.